Michael Ellenbogen, who serves as a director for Evolv Technologies Holdings, Inc., finalized the sale of 80,745 shares of the company's Class A Common Stock on May 15, 2026. This disposition amounted to a total value of $454,594. The transaction was not executed as a single block sale; rather, it involved multiple transactions with selling prices fluctuating between $5.53 and $5.77 per share.
Crucially, these sales were conducted pursuant to a Rule 10b5-1 trading plan that Mr. Ellenbogen had initially established on June 12, 2025. This structure indicates the planned nature of the divestiture, adhering to pre-arranged guidelines for selling company shares.
The current market data shows Evolv Technologies stock trading at $5.62 per share. This represents a decline of approximately 18% over the past week. The overall market capitalization of the company stands at $1.01 billion.
Background on Stock Holdings and Transactions
Before undertaking these sales, Mr. Ellenbogen had acquired the 80,745 shares in question by exercising stock options at a cost of $0.24 per share, which totaled $19,378. These specific options were subject to vesting schedules: they vested for 25% on January 31, 2018, and subsequently vest in 36 equal monthly installments until the expiration date of September 13, 2027.
Following the completion of these transactions, Mr. Ellenbogen's direct holdings comprise 2,083,961 shares of Class A Common Stock. Furthermore, his indirect stake includes 151,135 shares held through the Family Horizon Trust. He also maintains a remaining position consisting of 1,058,504 stock options (rights to purchase).
Recent Corporate Performance and Market Reaction
In parallel developments affecting the company's valuation, Evolv Technologies Holdings Inc. released its first-quarter earnings for 2026. The reported earnings per share (EPS) of -$0.03 met with analyst expectations. More significantly, the company achieved a substantial revenue beat, generating $46.3 million when analysts had projected $38.46 million. This represents an impressive surprise margin of 20.38%.
Despite these positive financial disclosures and operational metrics, the stock experienced a downturn during aftermarket trading. Compounding this, Evolv Technologies also issued updated guidance for its full-year 2026 revenue. This revised guidance was not initially incorporated into all financial data platforms.
TD Cowen provided commentary on the recent share price dip, reiterating a Buy rating while maintaining a $10.00 price target for Evolv Technologies. The firm specifically attributed the decline in share price to what it identified as incorrect financial data reporting across several platforms, noting that these systems failed to capture the company's updated financial metrics, which contributed to the market’s temporary fall.
These combined events underscore the critical importance of accurate and timely data representation within financial markets for proper valuation assessment.
Market Analysis and Valuation Perspectives
From an analytical standpoint, InvestingPro analysis suggests that EVLV currently appears overvalued relative to its intrinsic Fair Value. The platform also provides access to 6 additional ProTips specifically for EVLV, alongside comprehensive Pro Research Reports covering this stock and more than 1,400 other US equities.
The recent market movement highlights a divergence: strong fundamental performance indicators (revenue beat, increased guidance) contrasting with immediate share price weakness. The analyst commentary from TD Cowen emphasizes that the discrepancy was largely technical, stemming from data reporting failures rather than operational distress.